Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression

Eytan M. Stein; Stephane de Botton; Thomas Cluzeau; Arnaud Pigneux; Jane L. Liesveld; Rachel J. Cook; Philippe Rousselot; David A. Rizzieri; Thorsten Braun; Gail J. Roboz; Delphine Lebon; Mael Heiblig; Kristen Baker; Angela Volkert; Sofia Paul; Nisha Rajagopal; David A. Roth; Michael Kelly; Pierre Peterlin

doi:10.1080/10428194.2023.2243356

Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression

Eytan M. Stein, Stephane de Botton, Thomas Cluzeau, Arnaud Pigneux, Jane L. Liesveld, Rachel J. Cook, Philippe Rousselot, David A. Rizzieri, Thorsten Braun, Gail J. Roboz, Delphine Lebon, Mael Heiblig, Kristen Baker, Angela Volkert, Sofia Paul, Nisha Rajagopal, David A. Roth, Michael Kelly, Pierre Peterlin

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

4 Citations (Scopus)

Résumé

Tamibarotene-based therapy is a novel targeted approach for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with retinoic acid receptor alpha (RARA) gene overexpression. Approximately, 50% of higher-risk myelodysplastic syndrome (MDS) patients and approximately 30% of AML patients are positive for RARA overexpression using a blood-based biomarker test that measures RARA expression in peripheral blasts. A phase 2 study investigating the activity of tamibarotene in patients with RARA overexpression was conducted in patients with AML and MDS (NCT02807558). In 28 patients with R/R AML and RARA overexpression treated with tamibarotene in combination with azacitidine, the median overall survival was 5.9 months. In 21 response-evaluable patients, the complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate was 19%, and median time to initial CR/CRi was 1.2 months. The favorable safety profile and preliminary clinical activity support the development of combination therapies with tamibarotene in myeloid malignancies with RARA overexpression.

langue originale	Anglais
Pages (de - à)	1992-2001
Nombre de pages	10
journal	Leukemia and Lymphoma
Volume	64
Numéro de publication	12
Les DOIs	https://doi.org/10.1080/10428194.2023.2243356
état	Publié - 1 janv. 2023

Accès au document

10.1080/10428194.2023.2243356

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Stein, E. M., de Botton, S., Cluzeau, T., Pigneux, A., Liesveld, J. L., Cook, R. J., Rousselot, P., Rizzieri, D. A., Braun, T., Roboz, G. J., Lebon, D., Heiblig, M., Baker, K., Volkert, A., Paul, S., Rajagopal, N., Roth, D. A., Kelly, M., & Peterlin, P. (2023). Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression. Leukemia and Lymphoma, 64(12), 1992-2001. https://doi.org/10.1080/10428194.2023.2243356

@article{e51c826da9d94d989847830bace33ebf,

title = "Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression",

abstract = "Tamibarotene-based therapy is a novel targeted approach for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with retinoic acid receptor alpha (RARA) gene overexpression. Approximately, 50% of higher-risk myelodysplastic syndrome (MDS) patients and approximately 30% of AML patients are positive for RARA overexpression using a blood-based biomarker test that measures RARA expression in peripheral blasts. A phase 2 study investigating the activity of tamibarotene in patients with RARA overexpression was conducted in patients with AML and MDS (NCT02807558). In 28 patients with R/R AML and RARA overexpression treated with tamibarotene in combination with azacitidine, the median overall survival was 5.9 months. In 21 response-evaluable patients, the complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate was 19%, and median time to initial CR/CRi was 1.2 months. The favorable safety profile and preliminary clinical activity support the development of combination therapies with tamibarotene in myeloid malignancies with RARA overexpression.",

keywords = "Biomarker, RARA, SY-1425, retinoid, tamibarotene",

author = "Stein, {Eytan M.} and {de Botton}, Stephane and Thomas Cluzeau and Arnaud Pigneux and Liesveld, {Jane L.} and Cook, {Rachel J.} and Philippe Rousselot and Rizzieri, {David A.} and Thorsten Braun and Roboz, {Gail J.} and Delphine Lebon and Mael Heiblig and Kristen Baker and Angela Volkert and Sofia Paul and Nisha Rajagopal and Roth, {David A.} and Michael Kelly and Pierre Peterlin",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2023",

month = jan,

day = "1",

doi = "10.1080/10428194.2023.2243356",

language = "English",

volume = "64",

pages = "1992--2001",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "12",

}

Stein, EM, de Botton, S, Cluzeau, T, Pigneux, A, Liesveld, JL, Cook, RJ, Rousselot, P, Rizzieri, DA, Braun, T, Roboz, GJ, Lebon, D, Heiblig, M, Baker, K, Volkert, A, Paul, S, Rajagopal, N, Roth, DA, Kelly, M & Peterlin, P 2023, 'Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression', Leukemia and Lymphoma, VOL. 64, Numéro 12, p. 1992-2001. https://doi.org/10.1080/10428194.2023.2243356

Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression. / Stein, Eytan M.; de Botton, Stephane; Cluzeau, Thomas et al.
Dans: Leukemia and Lymphoma, Vol 64, Numéro 12, 01.01.2023, p. 1992-2001.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression

AU - Stein, Eytan M.

AU - de Botton, Stephane

AU - Cluzeau, Thomas

AU - Pigneux, Arnaud

AU - Liesveld, Jane L.

AU - Cook, Rachel J.

AU - Rousselot, Philippe

AU - Rizzieri, David A.

AU - Braun, Thorsten

AU - Roboz, Gail J.

AU - Lebon, Delphine

AU - Heiblig, Mael

AU - Baker, Kristen

AU - Volkert, Angela

AU - Paul, Sofia

AU - Rajagopal, Nisha

AU - Roth, David A.

AU - Kelly, Michael

AU - Peterlin, Pierre

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Tamibarotene-based therapy is a novel targeted approach for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with retinoic acid receptor alpha (RARA) gene overexpression. Approximately, 50% of higher-risk myelodysplastic syndrome (MDS) patients and approximately 30% of AML patients are positive for RARA overexpression using a blood-based biomarker test that measures RARA expression in peripheral blasts. A phase 2 study investigating the activity of tamibarotene in patients with RARA overexpression was conducted in patients with AML and MDS (NCT02807558). In 28 patients with R/R AML and RARA overexpression treated with tamibarotene in combination with azacitidine, the median overall survival was 5.9 months. In 21 response-evaluable patients, the complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate was 19%, and median time to initial CR/CRi was 1.2 months. The favorable safety profile and preliminary clinical activity support the development of combination therapies with tamibarotene in myeloid malignancies with RARA overexpression.

AB - Tamibarotene-based therapy is a novel targeted approach for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with retinoic acid receptor alpha (RARA) gene overexpression. Approximately, 50% of higher-risk myelodysplastic syndrome (MDS) patients and approximately 30% of AML patients are positive for RARA overexpression using a blood-based biomarker test that measures RARA expression in peripheral blasts. A phase 2 study investigating the activity of tamibarotene in patients with RARA overexpression was conducted in patients with AML and MDS (NCT02807558). In 28 patients with R/R AML and RARA overexpression treated with tamibarotene in combination with azacitidine, the median overall survival was 5.9 months. In 21 response-evaluable patients, the complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate was 19%, and median time to initial CR/CRi was 1.2 months. The favorable safety profile and preliminary clinical activity support the development of combination therapies with tamibarotene in myeloid malignancies with RARA overexpression.

KW - Biomarker

KW - RARA

KW - SY-1425

KW - retinoid

KW - tamibarotene

UR - http://www.scopus.com/inward/record.url?scp=85167836515&partnerID=8YFLogxK

U2 - 10.1080/10428194.2023.2243356

DO - 10.1080/10428194.2023.2243356

M3 - Article

C2 - 37571998

AN - SCOPUS:85167836515

SN - 1042-8194

VL - 64

SP - 1992

EP - 2001

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -